These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
128 related items for PubMed ID: 6407653
21. Complete biliary obstruction due to erythromycin estolate administration in an infant. Krowchuk D, Seashore JH. Pediatrics; 1979 Dec; 64(6):956-8. PubMed ID: 514726 [No Abstract] [Full Text] [Related]
23. [Jaundice caused by erythromycin estolate]. Persico L. Policlinico Prat; 1969 Jan 13; 76(2):33-41. PubMed ID: 4236690 [No Abstract] [Full Text] [Related]
24. Infantile hypertrophic pyloric stenosis related to ingestion of erythromycine estolate: A report of five cases. SanFilippo A. J Pediatr Surg; 1976 Apr 13; 11(2):177-80. PubMed ID: 1263054 [Abstract] [Full Text] [Related]
26. Comparison of erythromycin ethyl succinate, stearate and estolate treatments of group A streptococcal infections of the upper respiratory tract. Janicki RS, Garnham JC, Worland MC, Grundy WE, Thomas JR. Clin Pediatr (Phila); 1975 Dec 13; 14(12):1098-107. PubMed ID: 1104241 [Abstract] [Full Text] [Related]
28. Comparison of erythromycin base and estolate in gonococcal urethritis. Brown ST, Pedersen HB, Holmes KK. JAMA; 1977 Sep 26; 238(13):1371-3. PubMed ID: 408522 [Abstract] [Full Text] [Related]
30. A simple thin-layer chromatographic identification procedure for erythromycin base, stearate, estolate and ethylsuccinate. Vilim A, LeBelle MJ, Wilson WL, Graham KC. J Chromatogr; 1977 Mar 11; 133(1):239-44. PubMed ID: 838805 [No Abstract] [Full Text] [Related]
31. Pharmacokinetics of erythromycin ethylsuccinate and estolate in infants under 4 months of age. Patamasucon P, Kaojarern S, Kusmiesz H, Nelson JD. Antimicrob Agents Chemother; 1981 May 11; 19(5):736-9. PubMed ID: 6975059 [Abstract] [Full Text] [Related]
33. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. Pari L, Murugan P. Pharmacol Res; 2004 May 11; 49(5):481-6. PubMed ID: 14998559 [Abstract] [Full Text] [Related]
34. Erythromycin hepatotoxicity. A rare cause of a false-positive technetium-99m DISIDA study. Swayne LC, Kolc J. Clin Nucl Med; 1986 Jan 11; 11(1):10-2. PubMed ID: 3943237 [Abstract] [Full Text] [Related]
35. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. Croteau D, Bergeron MG, LeBel M. Antimicrob Agents Chemother; 1988 Apr 11; 32(4):561-5. PubMed ID: 3259856 [Abstract] [Full Text] [Related]
36. Case study: Drug interference in clinical chemistry. Hansen JL, Swanson LN. Am J Med Technol; 1981 Mar 11; 47(3):189-91. PubMed ID: 7223765 [No Abstract] [Full Text] [Related]
37. [Controlled study of the liver-protective effect of cycloxilic acid in a form of iatrogenic liver disease]. Neuman M, Fluteau G. Clin Ter; 1978 Nov 15; 87(3):243-64. PubMed ID: 380876 [No Abstract] [Full Text] [Related]